NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
H. Lee Moffitt Cancer Center and Research Institute
University of Hawaii
British Columbia Cancer Agency
Indiana University
Medical College of Wisconsin
M.D. Anderson Cancer Center
Pfizer